In this study, we trained various ML models to evaluate which combination of selected subsets of non-invasive variables could accurately predict CSF Aβ42, p-tau, and t-tau biomarker levels in a cohort of patients with mild-moderate AD(AD). The gene discussed is MAPT; the disease is Alzheimer disease.